This site is intended for healthcare professionals
Clinical trials
  • Home
  • /
  • Clinical trials
  • /
  • Cabometyx
  • /
  • Study of Cabozantinib (XL184) vs Placebo in Subjec...
Clinical trial

Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)

Read time: 1 mins
Last updated:5th May 2021
Identifier: NCT01908426
Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib (CELESTIAL)


ClinicalTrials.gov ID: NCT01908426

Sponsor: Exelixis
Information provided by: Exelixis (Responsible Party)
Last Update Posted: 2021-05-06

Brief Summary:
The purpose of this study is to evaluate the effect of Cabozantinib (XL184) compared with placebo on overall survival in subjects with advanced hepatocellular carcinoma who have received prior sorafenib.

Official Title:
A Phase 3, Randomized, Double-blind, Controlled Study of Cabozantinib (XL184) vs Placebo in Subjects With Hepatocellular Carcinoma Who Have Received Prior Sorafenib

Intervention / Treatment:
- Drug: Cabozantinib tablets
- Drug: Placebo tablets

Category Value
Study Start (Actual) 2013-09-26
Primary Completion (Actual) 2017-10-16
Study Completion (Actual) 2021-01-12
Enrollment (Actual) 707
Study Type Interventional
Phase Phase 3
Other Study ID Numbers
XL184-309


View full details